BioAtla Says FDA Clears IND Application For BA3361 For The Treatment Of Multiple Tumors
Biotechnology company BioAtla, Inc. (BCAB) announced Monday that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3361 (CAB-Nectin-4) antibody drug conjugate (ADC) for the treatment of multiple tumor types.
Source: rttnews.com